Leading translational and experimental medicine team to deliver novel treatments, including ALKS 2680, for neurological, psychiatric and rare diseases. We drive cross-functional teams to create detailed research and clinical development strategies and execute plans that are informed by the voice of the patient, unmet healthcare needs, commercial opportunity, disease etiology and biomarkers. We strive for logical translation from discovery to development, studies in healthy volunteers to patients, and development to commercialization.

As a very early BlackThorn employee, I helped build BlackThorn’s novel human biology-driven neuroscience pipeline and clinical development strategies and novel technological capabilities. Created translational and Phase 1-2 clinical strategies and implementation plans, including for BTRX-246040 and other BTRX compounds. Identified and operationalized novel digital patient monitoring technologies, multi-modal biomarkers, quantitative behavioral and clinical endpoints to measure efficacy and advance programs.

Develop and lead strategic R&D programs in drug target identification and validation, preclinical disease models, clinical biomarkers and behavioral assessments, digital phenotyping, pharmaceutical and digital therapeutics. Executive officer at DELSIA LLC, Autism Speaks' venture philanthropy affiliate.

Project Team Leader and Discovery Research Laboratory Head focused on discovery research strategy, new target identification and validation, and translation into early stage clinical development.

Discovery Research Laboratory Head, Project Team Leader and Selincro Product Development Team member focused on discovery and development of novel CNS therapeutics.